These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 34122422)

  • 21. Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Gupta K; Uchel T; Karamian G; Loschner A
    Cancer Treat Res Commun; 2021; 28():100439. PubMed ID: 34333246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
    Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
    Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
    Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential role of lung microbiota and lauroylcarnitine in T-cell activation associated with checkpoint inhibitor pneumonitis.
    Yu W; Wang K; He Y; Shang Y; Hu X; Deng X; Zhao L; Ma X; Mu X; Li R; Gao Z
    EBioMedicine; 2024 Aug; 106():105267. PubMed ID: 39098109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
    Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
    J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer.
    Velimirovic M; Brignola M; Chheng E; Smith M; Hassan KA
    Curr Treat Options Oncol; 2024 Oct; 25(10):1297-1311. PubMed ID: 39302574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
    Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
    Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
    Reuss JE; Suresh K; Naidoo J
    Curr Oncol Rep; 2020 May; 22(6):56. PubMed ID: 32415399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.
    Hu X; Wang L; Shang B; Wang J; Sun J; Liang B; Su L; You W; Jiang S
    Front Immunol; 2023; 14():1094414. PubMed ID: 36949956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
    Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
    J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors.
    Shibata Y; Murakami S; Kato T
    Expert Opin Drug Saf; 2021 May; 20(5):537-547. PubMed ID: 33650443
    [No Abstract]   [Full Text] [Related]  

  • 37. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.
    Shannon VR
    Curr Opin Pulm Med; 2020 Jul; 26(4):326-340. PubMed ID: 32452900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
    Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
    Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Checkpoint Inhibitor-Related Pneumonitis.
    Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
    Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.